Effect of irbesartan combined with atorvastatin on C reactive protein and cystatin C of patients with diabetic nephropathy
10.7619/jcmp.201721009
- VernacularTitle:厄贝沙坦联合阿托伐他汀治疗对糖尿病肾病患者C反应蛋白及胱抑素C的影响
- Author:
Li LIU
1
;
Mingxin LIU
;
Shihui NIU
;
Zejun LU
;
Nana WANG
;
Ling ZHANG
Author Information
1. 安徽省合肥市第二人民医院肾内科
- Keywords:
irbesartan;
atorvastatin;
diabetic nephropathy;
C-reactive protein;
cystatin C
- From:
Journal of Clinical Medicine in Practice
2017;21(21):33-35
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of irbesartan combined with atorvastatin on C reactive protein and cystatin C of patients with diabetic nephropathy.Methods A total of 60 diabetic nephropathy patients were selected and randomly divided into observation group and control group,30 cases in each group.The control group was treated with conventional treatment.On the basis of the control group,the observation group was treated with irbesartan and atorvastatin.Effect,CRP,renal function and cystatin C level were compared between two groups.Results In the observation group,the total effective rate was 95.0％,which was significantly higher than 75.0％ of control group (P ＜ 0.05).In the observation group,the TC,MAP after treatment were significantly lower than the control group (P ＜ 0.05),CRP was significantly lower than the control group (P ＜ 0.05).In the observation group,levels of Scr,UAER,CysC after treatment were significantly lower than the control group (P ＜ 0.05).There was no significant difference of adverse reactions between two groups (P ＞ 0.05).Conclusion Irbesartan combined with atorvastatin can significantly improve the levels of CRP and CysC in patients with diabetic nephropathy,reduce inflammatory response,improve renal function damage,improve treatment effect and delay the progress of the disease.
